TY  - JOUR
AU  - Kostadinović, Jelena
AU  - Popadić, Višeslav
AU  - Klašnja, Slobodan
AU  - Klisić, Aleksandra
AU  - Kotur-Stevuljević, Jelena
AU  - Andrić, Zoran
AU  - Zdravković, Marija
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4629
AB  - The clinical efficacy of chemotherapy, as a recognized therapeutic approach for malignant 
diseases,   usually   has   certain   limitations   due   to   its   cardiotoxicity   (CT)   and   consequent   
cardiomyopathy,  or  even  heart  failure.  CT
  is  defined  as  any  cardiac  injury  connected  with  
oncology treatment, whether it is chemo
-, radio
-, targeted or immunotherapy, or cancer by itself, 
and it represents a great challenge for clinicians in everyday practice. A wide spectrum of factors 
related t
o chemotherapy (type of drug, dose during each cycle, cumulative dose, schedule, method 
of  application,  combination  with  other  cardiotoxic  drugs  or  association  with  radiotherapy)  and  
patient  characteristics  (age,  presence  of  cardiovascular  risk  factors,  pr
evious  cardiovascular  
disease)  are  the  determining  factors  that  influence  the  frequency  of  CT.  Imaging  methods  for  
morphological  and  functional  monitoring  of  the  heart  muscle  are  used  for  monitoring  CT.  The  
quest  for  diagnostic  tools  for  early  CT  detection 
is  of  great  significance.  In  line  with  this,  the  
measurement  of  some  cardiac  biomarkers  has  found  its  place  in  clinical  settings  as  an  early  
determinant of myocardial injury. Therefore, in this review article, special attention will be paid 
to  certain  wel
l-established,  as  well  as  certain  novel  cardiac  biomarkers,  and  their  role  in  
recognizing asymptomatic CT, in order to gain deeper insight into their diagnostic utility.
AB  - Klinička  efikasnost  hemioterapije,  kao  priznatog  terapeutskog  pristupa  malignim 
bolestima, obično ima određena ograničenja zbog svoje kardiotoksičnosti (KT), te posledične 
kardiomiopatije, pa čak i srčane insuficijencije. KT se definiše kao svaka povreda miokarda 
povezana  s  lečenjem  raka,  uzimajući  u  obzir  hemioterapiju,  radioterapiju,  biološku  ili 
imunoterapiju,  kao  i  sam  karcinom,  te  predstavlja veliki  izazov  za  kliničare 
u  svakodnevnoj  
praksi. Širok spektar faktora povezanih s hemioterapijom (vrsta leka, doza tokom svakog ciklusa, 
kumulativna doza, raspored, način primene, kombinacija s drugim kardiotoksičnim lekovima ili 
povezanost s radioterapijom) i karakteristike bolesnika (dob, prisutnost faktora kardiovaskularnog 
rizika, prethodne kardiovaskularne bolesti), odlučujući su faktori koji utiču na učestalost KT. Za 
praćenje KT koriste se radiološke metode za morfološko i funkcionalno praćenje srčanog mišića. 
Potraga za dij
agnostičkim alatima za rano otkrivanje KT od velikog je značaja. U skladu s tim, 
merenje nekih srčanih biomarkera kao rane determinante povrede miokarda našlo je svoje mesto 
u kliničkim okruženjima. Stoga 
će u ovom preglednom članku posebna pažnja biti po
sve
ć
ena 
nekim  dobro  utvrđenim,  kao  i  nekim  novim  srčanim  biomarkerima,  i  njihovoj  ulozi  u 
prepoznavanju asimptomatske KT, kako bi se stekao dublji uvid u njihovu dijagnostičku korisnost 
i neželjene efekte lekova koji se primenjuju u terapiji karcinoma.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
T2  - Arhiv za farmaciju
T1  - Cardiotoxicity: Importance of biomarkers
T1  - Kardiotoksičnost: Važnost biomarkera
VL  - 73
IS  - 1
SP  - 1
EP  - 16
DO  - 10.5937/arhfarm73-40534
ER  - 

@article{
author = "Kostadinović, Jelena and Popadić, Višeslav and Klašnja, Slobodan and Klisić, Aleksandra and Kotur-Stevuljević, Jelena and Andrić, Zoran and Zdravković, Marija",
year = "2023",
abstract = "The clinical efficacy of chemotherapy, as a recognized therapeutic approach for malignant 
diseases,   usually   has   certain   limitations   due   to   its   cardiotoxicity   (CT)   and   consequent   
cardiomyopathy,  or  even  heart  failure.  CT
  is  defined  as  any  cardiac  injury  connected  with  
oncology treatment, whether it is chemo
-, radio
-, targeted or immunotherapy, or cancer by itself, 
and it represents a great challenge for clinicians in everyday practice. A wide spectrum of factors 
related t
o chemotherapy (type of drug, dose during each cycle, cumulative dose, schedule, method 
of  application,  combination  with  other  cardiotoxic  drugs  or  association  with  radiotherapy)  and  
patient  characteristics  (age,  presence  of  cardiovascular  risk  factors,  pr
evious  cardiovascular  
disease)  are  the  determining  factors  that  influence  the  frequency  of  CT.  Imaging  methods  for  
morphological  and  functional  monitoring  of  the  heart  muscle  are  used  for  monitoring  CT.  The  
quest  for  diagnostic  tools  for  early  CT  detection 
is  of  great  significance.  In  line  with  this,  the  
measurement  of  some  cardiac  biomarkers  has  found  its  place  in  clinical  settings  as  an  early  
determinant of myocardial injury. Therefore, in this review article, special attention will be paid 
to  certain  wel
l-established,  as  well  as  certain  novel  cardiac  biomarkers,  and  their  role  in  
recognizing asymptomatic CT, in order to gain deeper insight into their diagnostic utility., Klinička  efikasnost  hemioterapije,  kao  priznatog  terapeutskog  pristupa  malignim 
bolestima, obično ima određena ograničenja zbog svoje kardiotoksičnosti (KT), te posledične 
kardiomiopatije, pa čak i srčane insuficijencije. KT se definiše kao svaka povreda miokarda 
povezana  s  lečenjem  raka,  uzimajući  u  obzir  hemioterapiju,  radioterapiju,  biološku  ili 
imunoterapiju,  kao  i  sam  karcinom,  te  predstavlja veliki  izazov  za  kliničare 
u  svakodnevnoj  
praksi. Širok spektar faktora povezanih s hemioterapijom (vrsta leka, doza tokom svakog ciklusa, 
kumulativna doza, raspored, način primene, kombinacija s drugim kardiotoksičnim lekovima ili 
povezanost s radioterapijom) i karakteristike bolesnika (dob, prisutnost faktora kardiovaskularnog 
rizika, prethodne kardiovaskularne bolesti), odlučujući su faktori koji utiču na učestalost KT. Za 
praćenje KT koriste se radiološke metode za morfološko i funkcionalno praćenje srčanog mišića. 
Potraga za dij
agnostičkim alatima za rano otkrivanje KT od velikog je značaja. U skladu s tim, 
merenje nekih srčanih biomarkera kao rane determinante povrede miokarda našlo je svoje mesto 
u kliničkim okruženjima. Stoga 
će u ovom preglednom članku posebna pažnja biti po
sve
ć
ena 
nekim  dobro  utvrđenim,  kao  i  nekim  novim  srčanim  biomarkerima,  i  njihovoj  ulozi  u 
prepoznavanju asimptomatske KT, kako bi se stekao dublji uvid u njihovu dijagnostičku korisnost 
i neželjene efekte lekova koji se primenjuju u terapiji karcinoma.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Cardiotoxicity: Importance of biomarkers, Kardiotoksičnost: Važnost biomarkera",
volume = "73",
number = "1",
pages = "1-16",
doi = "10.5937/arhfarm73-40534"
}

Kostadinović, J., Popadić, V., Klašnja, S., Klisić, A., Kotur-Stevuljević, J., Andrić, Z.,& Zdravković, M.. (2023). Cardiotoxicity: Importance of biomarkers. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 73(1), 1-16.
https://doi.org/10.5937/arhfarm73-40534

Kostadinović J, Popadić V, Klašnja S, Klisić A, Kotur-Stevuljević J, Andrić Z, Zdravković M. Cardiotoxicity: Importance of biomarkers. in Arhiv za farmaciju. 2023;73(1):1-16.
doi:10.5937/arhfarm73-40534 .

Kostadinović, Jelena, Popadić, Višeslav, Klašnja, Slobodan, Klisić, Aleksandra, Kotur-Stevuljević, Jelena, Andrić, Zoran, Zdravković, Marija, "Cardiotoxicity: Importance of biomarkers" in Arhiv za farmaciju, 73, no. 1 (2023):1-16,
https://doi.org/10.5937/arhfarm73-40534 . .

TY  - JOUR
AU  - Rajkov, Branislava
AU  - Zdravković, Marija
AU  - Ninić, Ana
AU  - Brajković, Milica
AU  - Klašnja, Slobodan
AU  - Gardijan, Vera
AU  - Memon, Lidija
AU  - Munjas, Jelena
AU  - Mihajlović, Marija
AU  - Spasojević-Kalimanovska, Vesna
AU  - Radosavljević, Vojislav
AU  - Sopić, Miron
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4551
AB  - Purpose: Obstructive sleep apnea (OSA) is characterised by increased systemic inflammation, and is often accompanied with type 2 diabetes mellitus (T2DM) and cardiovascular disease. The aim of this investigation was to evaluate gene expression of resistin, its receptor CAP1 and CD36 as the indicators of the inflammatory changes in PBMCs in relation to the severity of OSA, and the presence of type 2 diabetes mellitus (T2DM) in OSA. Methods: Severity of OSA was defined by the apnea/hypopnea index (AHI): AHI < 30: mild to moderate OSA (MM-OSA), AHI ≥ 30: severe OSA (S-OSA). Presence of T2DM was captured: OSA with T2DM (OSA + T2DM), OSA without T2DM (OSA-T2DM). PBMC resistin, CAP1, and CD36 mRNA were determined by real-time PCR. Results: Resistin mRNA was significantly upregulated in S-OSA (N = 54) compared to the MM-OSA (N = 52, P = 0.043); CAP1 and CD36 mRNA levels did not differ between the groups (P = 0.302; P = 0.166, respectively). Resistin mRNA was significantly upregulated in OSA + T2DM (N = 29) compared to the OSA-T2DM (N = 77, P = 0.029); CAP1 and CD36 mRNA levels did not differ between the groups (P = 0.662; P = 0.108, respectively). AHI and T2DM were independent predictors of resistin mRNA above the 75th percentile (OR = 3.717 [1.152–11.991]; OR = 3.261 [1.000–10.630], P = 0.042 respectively). Conclusion: Resistin gene upregulation in S-OSA indicates its possible contribution to increased inflammation in S-OSA and makes it a possible marker of the disease severity. Resistin gene upregulation in OSA + T2DM suggests that a joint effect of these two comorbidities may have a major contribution to increased inflammation and complications that arise from this state.
PB  - Springer Nature
T2  - Sleep and Breathing
T1  - Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus
DO  - 10.1007/s11325-023-02809-0
ER  - 

@article{
author = "Rajkov, Branislava and Zdravković, Marija and Ninić, Ana and Brajković, Milica and Klašnja, Slobodan and Gardijan, Vera and Memon, Lidija and Munjas, Jelena and Mihajlović, Marija and Spasojević-Kalimanovska, Vesna and Radosavljević, Vojislav and Sopić, Miron",
year = "2023",
abstract = "Purpose: Obstructive sleep apnea (OSA) is characterised by increased systemic inflammation, and is often accompanied with type 2 diabetes mellitus (T2DM) and cardiovascular disease. The aim of this investigation was to evaluate gene expression of resistin, its receptor CAP1 and CD36 as the indicators of the inflammatory changes in PBMCs in relation to the severity of OSA, and the presence of type 2 diabetes mellitus (T2DM) in OSA. Methods: Severity of OSA was defined by the apnea/hypopnea index (AHI): AHI < 30: mild to moderate OSA (MM-OSA), AHI ≥ 30: severe OSA (S-OSA). Presence of T2DM was captured: OSA with T2DM (OSA + T2DM), OSA without T2DM (OSA-T2DM). PBMC resistin, CAP1, and CD36 mRNA were determined by real-time PCR. Results: Resistin mRNA was significantly upregulated in S-OSA (N = 54) compared to the MM-OSA (N = 52, P = 0.043); CAP1 and CD36 mRNA levels did not differ between the groups (P = 0.302; P = 0.166, respectively). Resistin mRNA was significantly upregulated in OSA + T2DM (N = 29) compared to the OSA-T2DM (N = 77, P = 0.029); CAP1 and CD36 mRNA levels did not differ between the groups (P = 0.662; P = 0.108, respectively). AHI and T2DM were independent predictors of resistin mRNA above the 75th percentile (OR = 3.717 [1.152–11.991]; OR = 3.261 [1.000–10.630], P = 0.042 respectively). Conclusion: Resistin gene upregulation in S-OSA indicates its possible contribution to increased inflammation in S-OSA and makes it a possible marker of the disease severity. Resistin gene upregulation in OSA + T2DM suggests that a joint effect of these two comorbidities may have a major contribution to increased inflammation and complications that arise from this state.",
publisher = "Springer Nature",
journal = "Sleep and Breathing",
title = "Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus",
doi = "10.1007/s11325-023-02809-0"
}

Rajkov, B., Zdravković, M., Ninić, A., Brajković, M., Klašnja, S., Gardijan, V., Memon, L., Munjas, J., Mihajlović, M., Spasojević-Kalimanovska, V., Radosavljević, V.,& Sopić, M.. (2023). Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus. in Sleep and Breathing
Springer Nature..
https://doi.org/10.1007/s11325-023-02809-0

Rajkov B, Zdravković M, Ninić A, Brajković M, Klašnja S, Gardijan V, Memon L, Munjas J, Mihajlović M, Spasojević-Kalimanovska V, Radosavljević V, Sopić M. Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus. in Sleep and Breathing. 2023;.
doi:10.1007/s11325-023-02809-0 .

Rajkov, Branislava, Zdravković, Marija, Ninić, Ana, Brajković, Milica, Klašnja, Slobodan, Gardijan, Vera, Memon, Lidija, Munjas, Jelena, Mihajlović, Marija, Spasojević-Kalimanovska, Vesna, Radosavljević, Vojislav, Sopić, Miron, "Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus" in Sleep and Breathing (2023),
https://doi.org/10.1007/s11325-023-02809-0 . .